All In Biotech

Drug Trial Radar · NCT05009992

Combination Therapy for the Treatment of Diffuse Midline Gliomas

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Oct 20, 2021

Primary completion

Dec 31, 2027

Study completion Jun 30, 2029

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Chad-Tough Defeat DIPG Foundation; Mithil Prasad Foundation; Storm the Heavens Fund; National Institute of Neurological Disorders and Stroke (NINDS); Jazz Pharmaceuticals; Neeve Kolte and Brave Ronil Foundation; Will Meeker Foundation; CV Biomanufacturing; Tough2gether Foundation
First posted
Aug 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. This trial will utilize an adaptive platform design in that the different treatment arms for each cohort will be opened and closed based on ongoing preclinical investigation as well as evolving outcome data from the trial. Novel agents will be continuously added to this study as pre-clinical data emerge to suggest additive or synergistic activity when combined ONC201. Should a novel agent not have an RP2D at the time of incorporation into this study, a phase 1 lead-in will be performed prior to initiation of combination therapy (via study amendment).

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Recurrent Diffuse Intrinsic Pontine Glioma
  • Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
  • Recurrent WHO Grade III Glioma
  • WHO Grade III Glioma

Interventions

  • ONC201Drug

    Given orally (PO)

  • Radiation TherapyRadiation

    Undergo radiation therapy

  • PaxalisibDrug

    Given PO

  • DNX-2401Drug

    DNX-2401 is an oncolytic adenovirus that will be administered through direct intratumoral infusion of DNX-2401 via a specialized Neuro Ventricular Cannula.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B OnlyTime frame: 6 months after diagnosis
  2. Progression-free survival at 6 months (PFS6) - Cohorts 2A, 2B OnlyTime frame: 6 months after diagnosis
  3. Overall survival at 7 months (OS7) - Cohort 3A & 3B OnlyTime frame: 7 months after administration of ONC201 in the maintenance phase
  4. Proportion of participants reporting dose-limiting toxicities (DLTs) (Cohort 4)Time frame: Up through the first cycle of maintenance therapy, approximately 8 months
  5. Number of participants requiring dose modification through first cycle of maintenance (Cohort 5)Time frame: Up through the first cycle of maintenance therapy, approximately 8 months
  6. Maximum tolerated number of intratumor infusions of DNX-2401, with a maximum of 6, in participants with thalamic or pontine DMG who have completed radiotherapy (Cohort 6)Time frame: A maximum of 6 infusions will be administered every 30 days - approximately 8 months

Locations

32 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • University of California, San Diego / Rady Children's Hospital, San Diego

    San Diego, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Indiana University Riley Children's Hospital

    Indianapolis, Indiana · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana-Farber Cancer Institute Harvard University

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Children's Hospital Minnesota

    Minneapolis, Minnesota · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Hackensack Meridian Health

    Hackensack, New Jersey · Recruiting

  • New York University

    New York, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Women and Children's Hospital

    Adelaide, Australia · Recruiting

  • Sydney Children's Hospital

    Sydney, Australia · Active not recruiting

  • John Hunter Children's Hospital

    New Lambton Heights, New South Wales, Australia · Recruiting

  • The Children's Hospital at Westmead

    Westmead, New South Wales, Australia · Active not recruiting

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia · Active not recruiting

  • Monash Children's Hospital

    Clayton, Victoria, Australia · Recruiting

  • The Royal Children's Hospital Melbourne

    Melbourne, Victoria, Australia · Active not recruiting

  • Perth Children's Hospital

    Nedlands, Washington, Australia · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center

    Tel HaShomer, Ramat Gan, Israel · Recruiting

  • Princess Maxima Center

    Utrecht, Netherlands · Active not recruiting

  • Starship Children's Hospital

    Auckland, New Zealand · Recruiting

  • The University Children's Hospital in Zurich

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.